EVOLVE SIGNED
Extracellular Vesicle-Internalizing Receptors (EVIRs) for Cancer ImmunoGeneTherapy
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0EVOLVE project word cloud
Explore the words cloud of the EVOLVE project. It provides you a very rough idea of what is the project "EVOLVE" about.
Project "EVOLVE" data sheet
The following table provides information about the project.
| Coordinator |
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Organization address contact info |
| Coordinator Country | Switzerland [CH] |
| Total cost | 1˙958˙919 € |
| EC max contribution | 1˙958˙919 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2016-COG |
| Funding Scheme | ERC-COG |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-07-01 to 2022-06-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE | CH (LAUSANNE) | coordinator | 1˙958˙919.00 |
Map
Project objective
We are witnessing transformative results in the clinical application of both cancer immunotherapies and gene transfer technologies. Tumor vaccines are a specific modality of cancer immunotherapy. Similar to vaccination against pathogens, tumor vaccines are designed to elicit a specific immune response against cancer. They are based on the administration of inactivated cancer cells or tumor antigens, or the inoculation of antigen-presenting cells (APCs) previously exposed to tumor antigens. In spite of significant development and testing, tumor vaccines have largely delivered unsatisfactory clinical results. Indeed, while some patients show dramatic and durable cancer regressions, many do not respond, highlighting both the potential and the shortcomings of current vaccination strategies. Hence, identifying and abating the barriers to effective cancer vaccines is key to broadening their therapeutic reach. The goal of EVOLVE (EVirs to Optimize and Leverage Vaccines for cancer Eradication) is to propel the development of effective APC-based tumor vaccines using an innovative strategy that overcomes several key hurdles associated with available treatments. EVOLVE puts forward a novel APC engineering platform whereby chimeric receptors are used to both enable the specific and efficient uptake of cancer-derived extracellular vesicles (EVs) into APCs, and to promote the cross-presentation of EV-associated tumor antigens for stimulating anti-tumor immunity. EVOLVE also envisions a combination of ancillary ‘outside of the box’ interventions, primarily based on further APC engineering combined with innovative pre-conditioning of the tumor microenvironment, to facilitate the deployment of effective APC-driven, T-cellmediated anti-tumor immunity. Further to preclinical trials in mouse models of breast cancer and melanoma, our APC platform will be used to prospectively identify novel human melanoma antigens and reactive T cell clones for broader immunotherapy applications.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Chiara Cianciaruso, Tim Beltraminelli, Florent Duval, Sina Nassiri, Romain Hamelin, André Mozes, Hector Gallart-Ayala, Gerardo Ceada Torres, Bruno Torchia, Carola H. Ries, Julijana Ivanisevic, Michele De Palma Molecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles published pages: 3062-3080.e11, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2019.05.008 |
Cell Reports 27/10 | 2020-01-29 |
| 2019 |
Caleb R. Perez, Michele De Palma Engineering dendritic cell vaccines to improve cancer immunotherapy published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-019-13368-y |
Nature Communications 10/1 | 2020-01-29 |
| 2018 |
Mario Leonardo Squadrito, Chiara Cianciaruso, Sarah K Hansen, Michele De Palma EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens published pages: 183-186, ISSN: 1548-7091, DOI: 10.1038/nmeth.4579 |
Nature Methods 15/3 | 2019-03-11 |
| 2019 |
Ioanna Keklikoglou, Chiara Cianciaruso, Esra Güç, Mario Leonardo Squadrito, Laura M. Spring, Simon Tazzyman, Lore Lambein, Amanda Poissonnier, Gino B. Ferraro, Caroline Baer, Antonino Cassará, Alan Guichard, M. Luisa Iruela-Arispe, Claire E. Lewis, Lisa M. Coussens, Aditya Bardia, Rakesh K. Jain, Jeffrey W. Pollard, Michele De Palma Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models published pages: 190-202, ISSN: 1465-7392, DOI: 10.1038/s41556-018-0256-3 |
Nature Cell Biology 21/2 | 2019-03-11 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EVOLVE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EVOLVE" are provided by the European Opendata Portal: CORDIS opendata.